Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors.
about
General considerations on the biosafety of virus-derived vectors used in gene therapy and vaccinationSpecific activation of 2'-5'oligoadenylate synthetase gene promoter by hepatitis C virus-core protein: A potential for developing hepatitis C virus targeting gene therapyLive dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lungMagnetically targeted viral envelopes: a PET investigation of initial biodistributionHerpes simplex virus based gene therapy enhances the efficacy of mitomycin C for the treatment of human bladder transitional cell carcinomaGenetics for urologists.Gene therapy for thyroid cancer.Replication-selective oncolytic viruses in the treatment of cancer.Gene therapy and immunotherapy of prostate cancer: adenoviral-based strategies.Replication-competent herpes simplex vectors: design and applications.Drug insight: Cancer cell immortality-telomerase as a target for novel cancer gene therapies.An overview on the development of newcastle disease virus as an anti-cancer therapy.Coronavirus genetically redirected to the epidermal growth factor receptor exhibits effective antitumor activity against a malignant glioblastomaRNA interference in head and neck oncology.HSV Recombinant Vectors for Gene Therapy.DNA-dependent protein kinase and its inhibition in support of radiotherapy.Inorganic nanovectors for nucleic acid delivery.Enhanced combined tumor-specific oncolysis and suicide gene therapy for prostate cancer using M6 promoter.Evaluation of combined gene regulatory elements for transcriptional targeting of suicide gene expression to malignant melanoma.Quantification and characterization of the bystander effect in prostate cancer cells following adenovirus-mediated FasL expression.Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.Soluble receptor-mediated targeting of mouse hepatitis coronavirus to the human epidermal growth factor receptor.Intrinsic bio-signature of gene delivery nanocarriers may impair gene therapy goals.N-acetylcysteine augments adenovirus-mediated gene expression in human endothelial cells by enhancing transgene transcription and virus entry.Tumor-specific intravenous gene delivery using oncolytic adenoviruses.Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients.Alternative splicing as a novel of means of regulating the expression of therapeutic genes.Gene therapy for malignant glioma.
P2860
Q26850701-83F5EE4D-F3CE-4C33-B8A8-F4DAC5348291Q27488872-2F14149D-89F9-45A1-9C53-119D70EBAAA1Q30480068-0268DC19-CF20-4302-8489-3C00A1B2633DQ33617175-74D59146-3C32-41A4-938B-6D6A4016F41FQ34313378-5430FE71-5311-4DE4-B47E-371E5A8A07C1Q35817137-6649EFC2-8023-4F87-814A-6758C1119AFCQ35842601-CFEED466-E2D7-4B0B-9321-629616A7BDA3Q35912403-44F9C64C-7896-4613-87C1-8110C47057CEQ36258513-6910555E-928A-4DC0-BE48-256B6FAA815AQ36288909-2E4B4C5D-596E-43E3-A36D-56C8A02936ECQ36303872-543F86BD-7389-418F-9A8A-687350AF8C4EQ36568040-F7F978D8-C5C2-4985-909E-EE220B85EE15Q37256658-7FD7F91E-6847-4F1B-95F8-75779F94F705Q37406819-16CB7861-13BD-49B8-B5DF-3D28BE048A22Q37787777-F66617DF-5E94-43FA-9FBA-17E0747FFCDAQ38077808-3B83D2C9-266B-4C77-B33D-5018D647CEF4Q38383483-BF35FB02-CC2E-48B6-AF84-54874AFB246CQ39942987-5254AA31-21E4-477E-AA37-BF1D5547099EQ40600863-AA4663D8-333C-490A-81A0-67E5AFE61556Q40657886-E87C6818-0D8B-42D0-A6C6-23208BC64B5DQ40665345-A71848EE-37D9-4875-9F26-331953906188Q40670694-68655346-2C22-4E79-A513-96A1287836D7Q42259491-411BEDFB-20B5-4AAE-8E45-A457C39182C2Q43877179-21FD6693-4C76-4F73-B67C-682A3D0DBAC5Q44571557-E6B4457B-3C98-4BEA-8C64-F96125B35CC2Q44591603-6F5E4D83-F8CA-45FC-9007-632E58A9753DQ45714276-BC394016-EE7B-4843-BA76-261B7B2D3807Q45857497-35B7BC1C-6219-41A8-9AF5-C8EA81894563
P2860
Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Delivery systems intended for ...... ation competent viral vectors.
@ast
Delivery systems intended for ...... ation competent viral vectors.
@en
Delivery systems intended for ...... ation competent viral vectors.
@nl
type
label
Delivery systems intended for ...... ation competent viral vectors.
@ast
Delivery systems intended for ...... ation competent viral vectors.
@en
Delivery systems intended for ...... ation competent viral vectors.
@nl
prefLabel
Delivery systems intended for ...... ation competent viral vectors.
@ast
Delivery systems intended for ...... ation competent viral vectors.
@en
Delivery systems intended for ...... ation competent viral vectors.
@nl
P2093
P1476
Delivery systems intended for ...... ation competent viral vectors.
@en
P2093
P304
P356
10.1016/S1040-8428(01)00103-2
P577
2001-06-01T00:00:00Z